Previous close | 42.45 |
Open | 42.45 |
Bid | 34.10 |
Ask | 38.50 |
Strike | 80.00 |
Expiry date | 2024-01-19 |
Day's range | 42.45 - 42.45 |
Contract range | N/A |
Volume | |
Open interest | 126 |
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
Sanofi's (SNY) Nexviadyme is approved for the treatment of both late-onset Pompe disease and infantile-onset Pompe disease. Xenpozyme is approved for non-Central Nervous System (CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.